Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology

被引:214
作者
Detmer, J [1 ]
Lagier, R [1 ]
Flynn, J [1 ]
Zayati, C [1 ]
Kolberg, J [1 ]
Collins, M [1 ]
Urdea, M [1 ]
SanchezPescador, R [1 ]
机构
[1] CHIRON CORP,EMERYVILLE,CA 94608
关键词
D O I
10.1128/JCM.34.4.901-907.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In studies monitoring disease progression and therapeutic response, it is essential that the method used for hepatitis C virus (HCV) quantification not be influenced by genotypic variability. The branched DNA assay provides a reliable method for the quantification of HCV RNA. A modified set of oligonucleotide probes for the branched DNA assay was developed to enhance the efficiency of binding to genotypic variants of HCV. The improved branched DNA assay (HCV RNA 2.0) yielded highly reproducible quantification of hepatitis C virus RNA and displayed a nearly 600-fold dynamic range in quantification up to 120 Meg of HCV RNA per ml. The quantification limit was set at 0.2 Meg of HCV RNA per ml to ensure a specificity of greater than or equal to 95%. With this lowered quantification limit and the enhanced hybridization of the probes, the HCV RNA 2.0 assay exhibited a high level of sensitivity (96%) and was virtually unaffected by the genotypic variability of HCV. The HCV RNA 2.0 assay may be a useful tool for following HCV RNA levels throughout the course of disease, selecting patients for therapy, and evaluating therapeutic response.
引用
收藏
页码:901 / 907
页数:7
相关论文
共 57 条
  • [31] GENOTYPIC ANALYSIS OF HEPATITIS-C VIRUS IN AMERICAN PATIENTS
    MAHANEY, K
    TEDESCHI, V
    MAERTENS, G
    DIBISCEGLIE, AM
    VERGALLA, J
    HOOFNAGLE, JH
    SALLIE, R
    [J]. HEPATOLOGY, 1994, 20 (06) : 1405 - 1411
  • [32] VIRAL AND HOST FACTORS THAT CONTRIBUTE TO EFFICACY OF INTERFERON-ALPHA(2A) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS-C
    MATSUMOTO, A
    TANAKA, E
    SUZUKI, T
    OGATA, H
    KIYOSAWA, K
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (06) : 1273 - 1280
  • [33] PREDICTING INTERFERON THERAPY EFFICACY FROM HEPATITIS-C VIRUS GENOTYPE AND RNA TITER
    MITA, E
    HAYASHI, N
    HAGIWARA, H
    UEDA, K
    KANAZAWA, Y
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (05) : 977 - 982
  • [34] *NAT COMM CLIN LAB, 1986, NCCLS PUBL
  • [35] HEPATITIS-C VIRUS TYPE-1B(II) INFECTION IN FRANCE AND ITALY
    NOUSBAUM, JB
    POL, S
    NALPAS, B
    LANDAIS, P
    BERTHELOT, P
    BRECHOT, C
    GIGOU, M
    FERAY, C
    THIERS, V
    OKAMOTO, H
    MISHIRO, S
    POUSSIN, K
    PATERLINI, P
    RUMI, M
    COLOMBO, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 122 (03) : 161 - +
  • [36] OGATA N, 1991, P NATL ACAD SCI USA, V88, P3391
  • [37] GENETIC DRIFT OF HEPATITIS-C VIRUS DURING AN 8.2-YEAR INFECTION IN A CHIMPANZEE - VARIABILITY AND STABILITY
    OKAMOTO, H
    KOJIMA, M
    OKADA, SI
    YOSHIZAWA, H
    IIZUKA, H
    TANAKA, T
    MUCHMORE, EE
    PETERSON, DA
    ITO, Y
    MISHIRO, S
    [J]. VIROLOGY, 1992, 190 (02) : 894 - 899
  • [38] ORITO E, 1994, J MED VIROL, V44, P410, DOI 10.1002/jmv.1890440418
  • [39] INTERFERON THERAPY IN CHRONIC HEPATITIS-C VIRUS - EVIDENCE OF DIFFERENT OUTCOME WITH RESPECT TO DIFFERENT VIRAL STRAINS
    POZZATO, G
    MORETTI, M
    CROCE, LS
    SASSO, F
    KANEKO, S
    UNOURA, M
    KOBAYASHI, K
    CROVATTO, M
    SANTINI, G
    TIRIBELLI, C
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1995, 45 (04) : 445 - 450
  • [40] RASSAM S, 1994, VIRAL HEPATITIS LIVE, P642